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Materials and Methods: There were 365 evaluable patients 
with at least one year of follow-up for the development of 
rectal bleeding. Rectal bleeding was assessed using the 
Radiation Therapy Oncology Group (RTOG) late radiation 
morbidity scoring schema. There were 74 patients with Grade 
2 or more late rectal bleeding. For all patients, DNA was 
genotyped using Affymetrix Genome-Wide Human SNP Array 
6.0. A quality control test was performed with SNP missing 
rate > 5%, minor allele frequency (MAF) < 5%, and Hardy-
Weinberg equilibrium (p < 10E-5). As a result, 613,496 SNPs 
remained. For the analysis, we split the patients into two 
groups: a group of patients with Grade 0 or 1 late rectal 
bleeding and the other group of patients with Grade 2 or 
more.  
To predict late rectal bleeding toxicity, we designed a 
machine learning-based multi-SNP model. Our model mainly 
consists of two steps: in the first step, principal component 
analysis (PCA) is used to filter out irrelevant SNPs and in the 
second step L1-penalized regression (LASSO) is used to 
remove redundant SNPs and to build a sparse regression 
model. In particular, normal tissue complication probability 
(NTCP), which was calculated using logistic regression with a 
few principal components derived from the first step, was 
used as a response variable in the second step. For unbiased 
assessment of the predicted model, the dataset was split into 
two groups: training dataset (2/3 of samples) and validation 
dataset (1/3 of samples). In the model design, only the 
training dataset was used with 10-fold cross validation. After 
50 iterations of the proposed method, SNPs were ranked 
based on the frequency that each SNP was used in the LASSO 
models. In a manner of forward feature selection, the 
validation dataset was tested with the LASSO models that 
were constructed using the training dataset. The area under 
the receiver operating characteristic (ROC) curve (AUC) was 
used as a performance metric. 
Results: Using the training data, univariate analysis was 
performed using Chi-square test. With a threshold of 
p=0.001, 749 SNPs remained. These SNPs were fed into our 
model. The cross-validation with the training dataset 
resulted in AUC=0.85 (standard deviation: 0.02) and the best 
final model with the validation dataset resulted in AUC=0.68 
(p=0.004) with 360 SNPs as shown in Fig. 1. 
 
Conclusions: A novel machine learning method demonstrated 
that a large number of SNPs contribute to clinical 
radiosensitivity for the radiation-induced late rectal 
bleeding. However, evaluation on other datasets is necessary 
to validate our model.  
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Purpose/Objective: Single-nucleotide polymorphisms (SNPs) 
in the ataxia telangiectasia mutated (ATM) gene have been 
associated with clinical radiation pneumonitis, but those 
findings have not been correlated with the pulmonary 
function impairment. Therefore, we investigated the 
association between SNPs in the ATM gene and the risk of 
diffusing capacity of the lung for carbon monoxide (DLCO) 
change in patients with non–small-cell lung cancer (NSCLC) 
treated with radiation therapy (RT).  
Materials and Methods: From November 1998 through June 
2009, 448 consecutive patients with inoperable or 
unrespectable primary NSCLC underwent definitive (≥60 Gy) 
radio(chemo)therapy; exclusion criteria were patients with a 
history of thoracic surgery, RT, or lung cancer or those who 
did not have undergone pulmonary function test before and 
after RT within one year. Ultimately, 100 patients met the 
selection criteria for this study. We genotyped two SNPs of 
the ATM gene (rs189037 and rs228590), and assessed 
correlation with DLCO impairment using logistic regression 
analysis. 
Results: The dataset consisted of 58 men and 42 women, 
with a median age of 64 years (range, 38–83 years). Of all 
these patients, 86 were whites and 82% had stage III/IV 
diseases according to the 6th edition of the AJCC stage 
grouping criteria. The median mean lung dose was 17.5 Gy 
(range, 4.7–29.5 Gy). Median DLCO change within one year 
after RT was 0.81 (range 0.22-1.79). Early DLCO change (3-6 
months after RT) had the same range but the median value 
was 0.77. The genotype distribution of all studied SNPs was: 
rs189037, 29% AA, 49% AG, 22% GG; and rs228590, 33% CC, 
49% CT, 19% TT. Univariate and multivariate analyses showed 
that the AA genotype of ATM rs189037 was associated with 
significantly higher DLCO impairment after definitive 
radiation than the GG/AG genotypes (univariate beta 
regression coefficient -0.12; 95% confidence interval [CI], -
0.24~-0.008; P = 0.037; multivariate beta regression 
coefficient -0.10; 95% CI, -0.20~-0.005; P = 0.04). However, 
similar results were not observed for rs228590 (univariate 
beta regression coefficient -0.10; 95% CI, -0.25~-0.12; P = 
0.096). 
Conclusions: The AA genotype of ATM rs189037 was 
associated with higher risk of lung injury, compared with the 
GG/AG genotypes in patients with NSCLC treated with 
radio(chemo)therapy. This response marker may be used for 
guiding therapy intensity in an individual patient, which 
would further the goal of individualized therapy.  
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Purpose/Objective: Normal tissue toxicity sets the dose limit 
for radiotherapy (RT) in cancer treatment and hence has 
significance for its curative potential. Individual differences 
in the severity of radiation induced toxicity suggests that 
there is a possibility of dose escalation to the more 
radioresistant group. In theory prediction of individual 
radiosensitivity could augment cure rates of RT. From a 
previous study we have access to a cohort of 42 prostate 
cancer patients treated with External Beam RT (EBRT) and 
clinical data for radiation induced toxicity measured by anal 
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physiological methods and validated questionnaires. Ten 
single nucleotide polymorphisms (SNPs) have previously been 
suggested to be predictive of late radiation induced toxicity 
by GWAS studies or candidate gene studies. The objective of 
this study was to test the ten SNPs in this unique cohort. The 
strength of the reportings as well as the clinical data 
available served as the rationale for using our rather small 
cohort as a validation cohort. 
Materials and Methods: The patients in this cohort have 
received EBRT 70-78 Gy for prostate cancer with curative 
intent. Functional toxicity endpoints have been examined by 
sigmoidoscopy, manometry, endoanal ultrasonography and 
impedance planimetry in an earlier study. Objective 
endpoints include the Vienna Rectoscopy Score (VRS), cross 
sectional area (CSA) of rectum at distension, maximum 
resting pressure (MRP) and maximum squeezing pressure 
(MSP) of anal sphincters. The subjective measure RT-
Anorectal dysfunction score (RT-ARD) was obtained from the 
questionnaires. Biological material from the patients in this 
cohort is available from an established research biobank. The 
SNPs were investigated in DNA from fibroblasts with TaqMan 
SNP assays. Statistical analyses was carried out with Stata13. 
For each SNP (table I) the reported risk allele was identified 
and due to the small sample size a risk-allele average was 
created for each patient. This risk-allele average was 
correlated to RT-ARD, VRS, MRP, MSP and CSA by Spearman's 
rank correlation. 
 
Results: All SNPs in the cohort were in Hardy-Weinberg 
equilibrium. Preliminary results showed no statistically 
significant correlations between the risk-allele average and 
toxicity end points tested. Spearman´s rank correlations ρ 
(rho) were as follows: VRS ρ = 0.17 p = 0.33, MRP ρ = -0.08 p 
= 0.64, MSP ρ = 0.02 p = 0.91, CSA ρ = 0.03 p = 0.88, RT-ARD 
ρ = -0.26 p = 0.13. 
Conclusions: Preliminary results indicate no correlation 
between risk-allele average and late radiation toxicity end 
points tested. The cohort will be expanded with 234 patients 
having received the same treatment and with the same 
questionnaire data on morbidity.  
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Purpose/Objective: Radiation-induced lung toxicity (RILT) 
varies significantly between patients at similar doses to the 
lung and can seriously affect the quality of life. The 
identification of prognostic biomarkers for radiation-induced 
toxicity is crucial for personalized RT: to select patients for 
proton therapy or dose escalation. We hypothesized variation 
in the mitochondrial genome (mtDNA) is a biomarker for 
RILT, since mitochondria and RT have several processes in 
common, among which reactive oxygen species (ROS) 
production. 
Materials and Methods: Blood DNA was isolated from 372 
(training set, Maastricht) and 68 (test set, Ghent) lung cancer 
patients. After exclusion of patients that had surgery, had 
other tumors within 5 years prior to lung cancer, received a 
palliative dose or for which baseline dyspnea score was 
unknown, 277 and 53 patients were remaining for the training 
and test set respectively. Baseline dyspnea (at the start of 
RT) and maximal dyspnea 3-6 months after RT were scored 
according to the CTCAE version 3.0 criteria. The endpoint of 
analysis was dyspnea grade>=2 after RT. Additionally, DNA 
was obtained from fibroblasts of 21 breast cancer patients for 
which the toxicity grade after radiotherapy was known 
(LENT/SOMA criteria). mtDNA was resequenced using 
mitochips and homoplasmic deviations from the revised 
Cambridge reference sequence were recorded. Variants were 
classified into 7 functional categories based on their 
theoretical effect on OXPHOS function. 
Results: Using the 7 functional categories as input features, 
logistic regression analysis corrected for baseline dyspnea 
score resulted in an AUC of 0.78 for the training set, which 
was significantly better than the current international gold 
standard Mean Lung Dose (AUC 0.57; p < 0.001). The AUC for 
the test set was 0.66 but the power of the validation was 
limited due to the small sample size. Validation in a second 
external test set is ongoing. Additionally, using mtDNA 
variation data we were able to classify breast cancer patients 
in the correct toxicity group with 80% accuracy. 
Conclusions: Our data showed that mtDNA variation is a 
valuable biomarker for RILT. Furthermore, we have 
preliminary data in breast cancer patients that the predictive 
effect of mtDNA might be applicable to radiation toxicity in 
general. 
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Purpose/Objective: (1) To quantify the geometric and 
dosimetric variability of prostate contouring on US for low-
dose-rate brachytherapy. (2) To assess the dosimetric 
variability of registrations of T1-weighted MRI with C-arm 
cone beam CT (CBCT) and the currently performed US-CBCT 
registrations. 
Materials and Methods: VariSeed studies of eleven patients 
previously treated with low-dose-rate brachytherapy at our 
institute were enrolled in a multi-observer study. Six 
observers performed three sessions of prostate contouring on 
US and registrations of US- and MRI-CBCT. 
Prostate contours were sampled at 10 degree increments of 
the polar and azimuthal angles from the center of mass. The 
